Paksa Ang epekto ng Erlotinib na nagdudulot ng hindi kanais nais na sakit sa mga matatandang may non-small cell lung cancer
Hong, W., Bast, R., Hait, T., Kufe, D., Pollock, Ur., Weichselbaum, 3rd there’s r., Holand, M., et al. (2012). Tumor Medicine. People's Medical Publishing House, Incorporation.
Ang Erlotinib ay isang gamot bist du ginagamit pra sa mga uri ng kanser tulad ng chest cancer. Isa rin itong epidermal growth factor inhibitor. Partikular nitong tina-target ang tyrosine kinase, isang EFGR na madalas nakikita social fear mga anyo ng non-small cell lung cancer. Pinipigilan din nito ang mga abnormal mhh protein na nag-sisimula ng pagkalat ng mga cancer cells social fear katawan. Ang erlotinib ay mayroon mga di kanais-nais na epekto tulad ng diarrhea, mga rashes, exhaustion, at pagkawala ng hambre sa pagkain.
Mga siniping pahayag
1 . Erlotinib and gefitinib are mouth small molecule tyrosine kinase inhibitors (TKIs) of the skin growth aspect receptor. They have been studied along with chemotheraphy in large in the first range setting, although non-e shown improved efficiency outcomes in comparison to chemotherapy exclusively.
-- Ang erlotinib at gefinitib ay mga inhibitors ng tyrosine kinase (TKI) ng epidermal expansion factor receptor. Pareho silang pinag-aralan kasama ang chemotheraphy, ngunit walang pag-unlad ng resulta ang nangyari kumpara sa pag-aaral nila ng chemotherapy lang. (Hong, T. et al., 2010)
2 . Vandetanib can be described as TKI of VEGFR and EGFR getting tested in the clinic. It is strongly recommended that, besides complementing radiation treatment regimens, targeted agents can enhance the healing efficacy of radiation therapy. The combination of several VEGFR and EGFR to further improve target inhibition was analyzed with erlotinib in forty five patients with stage 3 nonsmall cellular lung tumor. The median survival from the patients in phase 2 of the examine was 12. 6 months and 52% had been alive in a single year. Zero pharmacokinetic actions were seen, and the most frequent adverse incidents were slight...